stockrow
Friday 6 November 2026
Export BIAF’s income statement to Excel — free account
bioAffinity Technologies, Inc.
BIAF Healthcare Diagnostics & Research
bioAffinity Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 million, down 34.2% from fiscal 2024.
- Revenue
- +19.0%
- EPS
- +87.5%
- Free cash flow
- −23.7%
- Total debt
- +569.7%
Quarter to June 2026, against a year earlier
2.73
0.13
+5.00%
Follow BIAF
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.72 | 3.04 | 0.33 | 0.47 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.33) | (5.34) | (0.79) | (1.27) | |
P/B ratio |
1.13 | 4.70 | 0.28 | 0.35 | |
Price to Tangible BV |
2.53 | 11.08 | 0.39 | 0.47 | |
EV/Sales |
0.40 | 2.60 | (0.61) | (0.64) | |
EV/EBITDA |
0.00 | 0.00 | 0.37 | 0.44 | |
EV/Operating CF |
(0.21) | (1.35) | 0.40 | 0.51 | |
EV/FCF |
(0.21) | (1.35) | 0.40 | 0.51 | |
Quick Ratio |
1.24 | 1.19 | 2.41 | 3.44 | |
Current Ratio |
1.44 | 1.36 | 2.60 | 3.65 | |
Net Debt/EBITDA |
0.57 | 0.71 | 1.92 | 3.44 | |
Debt/Assets |
7.28% | 7.74% | 6.20% | 1.58% | |
Debt/Equity |
0.15 | 0.17 | 0.09 | 0.02 | |
Asset Turnover |
0.95 | 0.84 | 0.71 | 0.75 | |
Operating CF/Net income |
0.95 | 0.89 | 0.82 | 0.49 | |
Capex/Depreciation |
(1.46) | (0.05) | 0.00 | 0.03 | |
Interest Coverage |
(285.03) | (246.05) | (239.47) | (424.59) | |
Research and Development Expense of Revenue |
55.44% | 50.59% | 41.99% | 32.77% | |
Selling, General and Administrative Expense of Revenue |
189.24% | 239.85% | 190.68% | 152.78% | |
Intangible Assets out of Total Assets |
0.27 | 0.27 | 0.19 | 0.19 | |
Share Based Compensation of Revenue |
51.97% | 1.06% | 4.15% | 4.65% | |
Graham Net Nets |
0.00 | 0.00 | 1.91 | 1.89 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(848.27%) | (296.36%) | (1,300.30%) | (707.62%) | |
Free Cash Flow Yield |
(272.26%) | (63.46%) | (462.09%) | (269.48%) | |
Revenue per Share |
4.33 | 4.51 | 13.87 | 20.34 | |
Operating CF per Share |
(9.18) | (10.76) | (22.30) | (34.88) | |
Capex per Share |
(0.26) | (0.02) | 0.00 | 0.05 | |
Free Cash Flow per Share |
(9.44) | (10.78) | (22.30) | (34.83) | |
Cash per Share |
6.97 | 10.33 | 56.18 | 107.87 | |
Shareholders Equity per Share |
10.81 | 12.21 | 63.39 | 125.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.81 | 12.21 | 63.39 | 125.21 | |
Free Cash Flow |
(3.29) | (3.23) | (2.56) | (2.48) | |
Working Capital |
1.18 | 1.16 | 4.66 | 6.25 | |
Capital Expenditures |
(0.09) | (0.01) | 0.00 | 0.00 | |
Net Current Asset Value |
0.01 | 0.06 | 3.88 | 5.97 | |
EV/EBIT |
0.00 | 0.00 | 0.35 | 0.42 | |
Capex to Sales |
0.06 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.66 | 0.82 | 0.84 | 0.89 | |
Average Payables |
1.07 | 1.11 | 0.87 | 0.86 | |
Average Inventory |
0.06 | 0.06 | 0.04 | 0.03 | |
Average Assets |
6.19 | 6.75 | 8.74 | 9.05 | |
Average Common Equity |
0.82 | 2.55 | 4.94 | 6.01 |
Columns are period end dates · fundamentals updated 26 Oct 2026